Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

French President Emmanuel Macron takes photos with his smartphone from a document held by German Chancellor Angela Merkel

French President Emmanuel Macron takes photos with his smartphone from a document held by German Chancellor Angela Merkel during a summit in Brussels on July 20, 2020. (Photo: John Thys/Pool/AFP via Getty Images)

Watchdog Shines Light on Big Pharma's 'Fierce' EU Lobbying Campaign Against Vaccine Patent Waiver

"The public is being left in the dark as to the demands, influencing strategies, and full firepower of the Big Pharma lobby at a time when the debate over who gets to keep monopoly control of Covid-19 patents is raging."

To preserve its stranglehold over global vaccine production, the pharmaceutical industry's army of lobbyists is waging an aggressive campaign to prevent European nations from supporting a temporary patent waiver backed by more than 100 nations around the world and recently endorsed by the United States.

Though flimsy European Union transparency rules have allowed Big Pharma to keep its lobbying efforts largely shrouded in secrecy, an analysis released Monday by the Corporate Europe Observatory (CEO) estimates that the pharmaceutical industry spends at least €36 million per year—roughly $44 million USD—attempting to influence European Union policy.

"There are several hundred lobby consultancies in Brussels, and over 65 firms have lobbyists with permanent access passes to the European Parliament."
—Corporate Europe Observatory

"The public is being left in the dark as to the demands, influencing strategies, and full firepower of the Big Pharma lobby at a time when the debate over who gets to keep monopoly control of Covid-19 patents is raging," the watchdog group said. "The stakes simply couldn't be higher."

CEO found that the the European Federation of Pharmaceutical Industries and Associations, Big Pharma's most prominent E.U. lobby group, ramped up lobbying spending by around 20% in 2020 as the pandemic raged across the globe and developing countries struggled to launch vaccination programs.

Those struggles continue in the present as pharmaceutical companies cling to their lucrative patent monopolies, barring the production of generic vaccines to boost the artificially scarce global supply while enriching their executives and shareholders.

Helping pharmaceutical companies to perpetuate deep inequities in vaccine distribution—described as "vaccine apartheid" by many observers—are powerful European nations such as Germany, the United Kingdom, and France, which have thus far refused to join the U.S. in supporting the waiver proposal first introduced at the World Trade Organization last October by India and South Africa.

As CEO noted in its new report, "mega-philanthropist Bill Gates and the pro-patent lobby are a powerful force influencing the E.U.'s response." Supporters of the patent waiver and other means of vaccine technology sharing, meanwhile, "face closed doors" in much of Europe, the watchdog group said.

"Figures highlighted by Deutsche Welle showed an extreme imbalance between opponents and proponents of the vaccine patents waiver: 140 meetings with pharma companies and their associations, 18 meetings with generic companies, and only one meeting with pro-waiver groups," CEO noted.

According to the new analysis, "pharma companies and lobby groups report employing a whopping 290 lobbyists (an estimated 104.75 full-time lobby jobs), and this figure does not include the 'hired gun' lobbyists at lobby consultancies."

"There are several hundred lobby consultancies in Brussels, and over 65 firms have lobbyists with permanent access passes to the European Parliament," CEO said. "We found 34 lobby consultancies in the Transparency Register reporting that they work for Big Pharma."

CEO's effort to shine light on Big Pharma's secretive and influential lobbying campaign comes just days before members of the European Parliament are set to decide the institution's formal position on the patent waiver, which has garnered high levels of public support across Europe. During a debate over the waiver last month, MEPs were split over whether to support the proposal.

Meanwhile, as Reuters reported, "negotiations reopened at the WTO on Monday, focused on a highly anticipated revised [patent waiver] draft submitted by India, South Africa, and dozens of other developing countries last week."

"A surprise U.S. shift earlier this month to support a patent waiver heaped pressure on remaining opponents like the European Union and Switzerland that are home to numerous drugmakers," Reuters noted. "But Monday's discussions—the 11th session since the initial waiver proposal in October—failed to achieve a breakthrough."

The WTO's TRIPs Council is scheduled to meet in Geneva next week to discuss the patent waiver. To win final approval, the proposal must receive unanimous support at the WTO—an uphill climb amid continued opposition from European leaders, Canada, and other rich nations.

As coronavirus cases and deaths remain high in countries that have had difficulties vaccinating their populations due to supply shortages, intellectual property barriers, and other factors, experts warned of dire consequences for the world if the patent waiver talks remain stagnant.

"Internationally, there's a real risk that the European Union could make this drag out, that their actions in Geneva and at the World Trade Organization could lead to a serious delay," Kenneth Haar, a researcher at CEO, told The Daily Poster on Tuesday. "That's a huge problem because time is of the essence."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
We need your help.

Support progressive journalism.

Common Dreams is not your average news site. We don't survive on clicks or advertising dollars. We rely entirely on your support. And without it, our independent progressive journalism simply wouldn’t exist. Every gift of every amount matters.

Join the fight and support our common dreams today.

Progressives Say 'Do What the People Want and Tax the Rich' to Pay for Infrastructure

"It is obvious that if we're going to address the needs of working families in this country, we need revenue," says Sen. Bernie Sanders, "and one way that we get that revenue is by demanding that the wealthiest people, the largest corporations are paying their fair share."

Jessica Corbett, staff writer ·


Doctors Without Borders Calls on BioNTech to Share Vaccine Tech With World

"The faster companies share the know-how, the faster we can put an end to this pandemic."

Andrea Germanos, staff writer ·


Over 30,000 US Veterans of Post-9/11 Wars Have Killed Themselves Since 2001

"As we come closer to the twentieth anniversary of the September 11th attacks, we must reflect on the mental health cost of the Global War on Terror."

Julia Conley, staff writer ·


Sunrise Ends 400-Mile Climate March With Arrests at Ted Cruz's House

The Gulf South marchers demand that Congress and the Biden White House pass bold climate jobs legislation, including a bill to create a Civilian Climate Corps.

Jessica Corbett, staff writer ·


Global Hopes in Doubt After G7 Fails to Meet Climate Finance Pledges for Poor Nations

"I'd have really hoped for a clearer signal on how and when we will be able to see the commitment to mobilize the $100 billion fulfilled."

Andrea Germanos, staff writer ·